Page 3 - Warren Huff News Today : Breaking News, Live Updates & Top Stories | Vimarsana

The FDA has accepted for Priority Review the NDA for omaveloxone for the treatment of Friedreich ataxia.

The CRL stated that the application for bardoxolone could not be approved in its current form due to a lack of data supporting claims of slowing kidney function loss and reducing kidney failure progression.

Reata Pharmaceuticals (RETA) has lost ~4% in the post-market Friday after the company announced that the U.S

Operator Ladies and gentlemen, thank you for standing by, and welcome to the Reata Pharmaceuticals' First Quarter 2021 Financial Results and Update on Development Programs Conference Call. An audio recording of today's webcast will be available shortly after the call today on Reata's website at reatapharma.com in the Investors section. Before the company proceeds with its remarks, please note the forward-looking statements disclosure in the company's press release. The company will be making forward-looking statements on today's call. There are many factors that could cause results to differ ...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Reata Announces the Appointments of Christy J. Oliger and Shamim Ruff to Its Board of Directors Reata Pharmaceuticals, Inc.April 15, 2021 GMT PLANO, Texas, April 15, 2021 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced the appointments of Christy J. Oliger and Shamim Ruff to its Board of Directors, effective April 15, 2021. “We are excited to welcome Ms. Ruff and Ms. Oliger to...